Fate Therapeutics (FATE) Net Income towards Common Stockholders (2012 - 2026)

Fate Therapeutics (FATE) has 15 years of Net Income towards Common Stockholders data on file, last reported at -$147.7 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 12.01% year-over-year to -$147.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$300.5 million (up 69.45% YoY) and the FY2025 annual result came in at -$524.7 million, up 5.48% from the prior year.
• Net Income towards Common Stockholders fell to -$147.7 million in Q1 2026, from -$32.5 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$32.5 million in Q4 2025 to a low of -$420.0 million in Q4 2024.
• A 5-year average of -$179.6 million and a median of -$155.3 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders tumbled 110.33% — and 2025, when it soared 92.26%.
• Tracing FATE's Net Income towards Common Stockholders over 5 years: stood at -$357.8 million in 2022, then decreased by 2.75% to -$367.6 million in 2023, then slipped by 14.24% to -$420.0 million in 2024, then soared by 92.26% to -$32.5 million in 2025, then plunged by 354.5% to -$147.7 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$147.7 million (Q1 2026), -$32.5 million (Q4 2025), and -$75.3 million (Q3 2025), per Business Quant data.